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InTRoDUCTIon
Nonalcoholic fatty liver disease 
(NAFLD) refers to a disease spectrum 
ranging from simple steatosis with no 
inflammation through hepatic necroin-
flammation (nonalcoholic steatohepatitis) 
to cirrhosis (1). It is strongly associated 
with obesity, insulin resistance and 
type 2 diabetes (T2D) and has become 
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the most frequent liver disease  
worldwide (1,2).
Over the last decade, it has become 
clear that inflammation has an important 
role in obesity and NAFLD (2). However, 
the detailed underlying mechanisms of 
obesity-induced inflammation are not 
fully understood. Important modulatory 
effects on both immunity and metabolism 
have been attributed to tumor necrosis 
factor (TNF), interleukin (IL)-1β and 
IL-18 (3). Many cytokines of the IL-1 
family are secreted as inactive precursors 
and require processing by proteases. One 
protease able to process both pro-IL-1β 
and pro-IL-18 to their bioactive forms is 
caspase-1, a cysteine protease regulated 
by a protein complex called the inflam-
masome. Indeed, recent studies showed 
that mice deficient for caspase-1 or indi-
vidual components of the inflammasome 
have improved insulin sensitivity and 
decreased liver steatosis in diet-induced 
obesity models (4,5). However, pro-
duction of active IL-1β and IL-18 is not 
exclusively dependent on caspase-1. 
Other proteases highly important for 
processing of cytokine precursors are 
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important for inducing insulin resistance 
and NAFLD, α-1-antitrypsin treatment 
might also be beneficial for the treatment 
of these conditions. In this study, we 
engaged a number of in vivo approaches 
to pursue the hypothesis that endog-
enous proteinase 3 is important in the 
induction of NAFLD and insulin resis-
tance in mouse models of diet-induced 
obesity and to assess whether treatment 
with α-1 antitrypsin protects against 
obesity-induced development of NAFLD 
and insulin resistance.
MATeRIALS AnD MeTHoDS
Animals
Casp-1–/–, ela–/–/ctsg–/– (neutrophil 
elastase/cathepsin G double knock-out 
mice; NE–/–/CG–/–) and ela–/–/prtn3–/–  
(neutrophil elastase/proteinase 3 double 
knock-out mice; NE–/–/PR3–/–) were back-
crossed to C57BL/6J background for at 
least 10 generations and have been de-
scribed previously (15,16). Age-matched 
wild-type C57BL/6J mice were used as 
controls and obtained from Charles River 
or Jackson Laboratories. Mice were housed 
in a pathogen-free facility and maintained 
at 23°C with water and food ad libitum and 
a 12 h:12 h light:dark cycle (lights on 6 am 
to 6 pm). All mice were 10- to 12-wk-old 
males at the start of diet intervention.  
Animal studies were approved by the 
Animal Welfare Committee of the Rad-
boudumc, Nijmegen, The Netherlands 
and the Washington University School of 
Medicine, St. Louis, Missouri, USA.
Diet Intervention and Treatment 
Regime
Male mice received a low-fat diet or a 
high-fat diet for 16 wks, providing 10% 
or 45% energy percent in the form of 
triglycerides (D12450B or D12451; Re-
search Diets). Regarding the experiments 
in which mice were treated with α-1 
antitrypsin or proteinase 3, a subgroup of 
mice receiving a high-fat diet was divided 
in bodyweight-matched treatment groups 
during the last 2 wks of dietary interven-
tion. These mice were injected five  
times (every other day for 10 d)  
However, endogenous proteinase 3 has 
not been investigated for its capability to 
induce insulin resistance and NAFLD in 
diet-induced obese animal models.
Proteinase 3 is strongly inhibited by 
the human protease inhibitor α-1 anti-
trypsin, a multifunctional protein with 
potent anti-inflammatory properties. It is 
primarily synthesized in the liver but is 
also expressed in other cell types includ-
ing neutrophils, monocytes and macro-
phages. Besides its capacity to inhibit 
proteinase 3, α-1 antitrypsin also blocks 
neutrophil elastase and cathepsin G 
(Figure 1) (11), as well as caspase-1 and 
caspase-3 (12,13). In addition, α-1 anti-
trypsin enhances the production of 
anti-inflammatory mediators such as 
IL-10 and IL1-Ra (14). In light of the 
recent evidence that both the caspase-1 
and the neutrophil serine  proteases are 
the neutrophil serine proteases. These 
proteases, namely neutrophil elastase, 
cathepsin G and proteinase 3, are re-
leased by neutrophils and are able to 
cleave/process membrane-bound TNF, 
mature TNF, pro-IL-1β and pro-IL-18, 
thereby regulating inflammatory re-
sponses (Figure 1). It is also known that 
a large proportion of the released serine 
proteases bind to the plasma membrane 
with their catalytic activity preserved 
(6,7). Recent studies showed that mice 
deficient for neutrophil elastase are 
resistant to high–fat–diet-induced body-
weight gain, insulin resistance (8,9) and 
fatty liver (9). Relatively little is known 
about proteinase 3 in relation to insu-
lin resistance and NAFLD. One study 
reported that a single injection of com-
mercially available proteinase 3 induced 
insulin resistance in healthy mice (10). 
Figure 1. The role of neutrophil serine proteases in inflammation. Following activation, 
neutrophils will release their serine proteases in the extracellular environment. A portion of 
these released serine proteases will bind to the membrane. Once released, serine prote-
ases (both membrane-bound and in the extracellular environment) are able to process 
(activate and/or inactivate) cytokines, thereby regulating inflammation. Human α-1 anti-
trypsin has potent anti-inflammatory properties. It complexes with proteinase 3, neutrophil 
elastase and cathepsin G, thereby preventing their enzymatic activities. It also inhibits 
caspase-1 and enhances the production of the anti-inflammatory mediators IL-10 and 
IL-1-Ra. All these actions result in a strong anti-inflammatory effect. PR3, proteinase 3; NE, 
neutrophil elastase; CG, cathepsin G; Casp-1, caspase-1; IL-1Ra, interleukin 1 receptor 
antagonist.
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compared with controls (18) (microarray 
data available; www.ebi.ac.uk/arrayex-
press; accession number E-MTAB-1765). 
These results were validated by qPCR 
analysis (Figure 2B). The observation 
that proteinase 3 mRNA expression, but 
not caspase-1, neutrophil elastase and 
cathepsin G mRNA expression, is upreg-
ulated in livers from animals with diet- 
and inflammation-induced NAFLD and 
insulin resistance suggests an unique 
role of this protease in the liver.
ne–/–/CG–/– and ne–/–/PR3–/– Mice 
Have Reduced Levels of Lipids in 
the Liver as well as Improved Insulin 
Sensitivity and Glucose Tolerance, 
Independently of Bodyweight
To further investigate the role of  
neutrophil serine proteases, especially 
proteinase 3, in diet-induced NAFLD 
and insulin resistance, we performed a 
16-wk high–fat-diet intervention study 
in which wild-type mice and animals de-
ficient for ela/ctsg (NE–/–/CG–/–) and ela/
prtn3 (NE–/–/PR3–/–) were compared (16).
Before the start of the diet interven-
tion, no differences in bodyweight were 
observed between the three genotypes. 
High–fat-diet feeding induced weight 
gain in all groups, although weight gain 
after high-fat diet was significantly less 
in both knock-out mice as compared 
with the wild-type animals (Figure 3A). 
No differences in weight gain were ob-
served between the two double knock-
out genotypes. No differences in food in-
take were observed between the groups.
To assess insulin sensitivity, insulin 
tolerance tests and oral glucose tolerance 
tests were performed. Both NE–/–/CG–/– and 
NE–/–/PR3–/– mice were more insulin sen-
sitive after high-fat diet when compared 
with wild-type mice. Insulin tolerance 
test area under the curve (AUC) values 
were significantly lower in NE–/–/CG–/– 
(p < 0.0001) and NE–/–/PR3–/– mice 
(p < 0.0001) when compared with the 
wild-type controls. Also the oral glucose 
tolerance tests AUC values were decreased 
in NE–/–/CG–/– (p = 0.02) and NE–/–/PR3–/– 
mice (p < 0.0001) when  compared with 
those of wild-type mice, indicating 
NanoDrop spectrophotometer (NanoDrop 
Technologies). Total RNA (1 μg) was 
reverse transcribed (iScript; Bio-Rad Lab-
oratories) and quantitative polymerase 
chain reaction (qPCR) was performed 
by SYBR Green-based quantification 
(Applied Biosystems). Primers were de-
veloped using Primer3 (Supplementary 
Table S1; http://primer3.ut.ee/). Primer 
pairs were exon-spanning. The genes 
Gapdh and B2m were chosen as endoge-
nous controls. Differences in expression 
were calculated by the 2ΔΔCt method (17).
Statistical Analysis
Data are represented as mean ± SEM 
unless stated otherwise. Data were ana-
lyzed using, as appropriate, the Student 
t test or analysis of variance followed 
by the Tukey post hoc test (GraphPad 
Prism 5.0). When necessary, results were 
log-transformed to normalize the data. A 
p value <0.05 was considered significant.
All supplementary materials are available 
online at www.molmed.org.
ReSULTS
Proteinase 3 expression Is Increased 
in Livers from High–Fat–Diet-Induced 
Insulin-Resistant Mice
To explore the role of proteinase 3 in 
diet-induced NAFLD and insulin resis-
tance, we first examined proteinase  
3 messenger RNA (mRNA) expression in 
liver tissues  obtained from independent 
studies investigating NAFLD and insulin 
resistance in mice. Relative expression 
of proteinase 3 (Prtn3) in the liver was 
increased after 4 wks of high–fat-diet 
feeding (2.7-fold induction; p = 0.0096). 
Noticeably, caspase-1, neutrophil elas-
tase (Elane) and cathepsin G (Ctsg) gene 
expression levels were not affected 
(Figure 2A). In addition, whole-genome 
expression profiling results showed that 
proteinase 3 expression was induced 
more than 80-fold (corrected p = 3.78E-08) 
in livers from arthritic mice that showed 
inflammatory-induced insulin resistance. 
Caspase-1, neutrophil elastase and cathep-
sin G expression were not affected when 
intraperitoneally (IP) with either α-1 
 antitrypsin ( Zemaira; 2.0 mg per injection) 
or proteinase 3 (0.25 mg/kg; Athens  
Research & Technology Inc.) in vehicle 
(phosphate-buffered saline (PBS)) or ve-
hicle alone. Also the low–fat-diet control 
group was treated with vehicle (five times 
every other day) for the last 10 d of 
dietary intervention. Insulin sensitivity 
was assessed by insulin tolerance tests 
and oral glucose tolerance tests. Mice 
were fasted for 4 h and overnight, respec-
tively, before IP injection with insulin 
(0.75 U/kg bodyweight) or oral glucose 
administration (2 g/kg D glucose; Life 
Technologies). Blood samples were taken 
by tail-cut at baseline and after 15, 30, 45, 
60, 90 and 120 min of insulin or glucose 
administration. Blood glucose concentra-
tions were measured with a blood glucose 
meter (Accu-Chek Avia; Roche Diagnos-
tics). At the end of the experiments, blood 
was collected in heparin-coated tubes and  
centrifuged to collect plasma. Liver and 
adipose tissue were weighed and collected 
for further analysis.
Histology/Immunohistochemistry
Hematoxylin and eosin (HE) staining 
of sections and detection of F4/80- 
positive macrophages were done using 
standard protocols. Quantification of 
lipid droplets in HE liver sections was 
performed by using the ImageJ software 
(http://rsbweb.nih.gov). Macrophages 
and crown-like structures were counted 
in four images per sample. Sections were 
scored in a blinded fashion.
Liver Triglycerides
For measuring liver triglycerides,  
l0% liver homogenates were prepared in 
buffer containing 250 nmol/L sucrose,  
1 mmol/L EDTA and 10 mmol/L  
Tris-HCL at pH 7.5. Triglycerides were 
determined enzymatically following 
manufacturers’ protocols (Liquicolor; 
Human GmbH).
RnA Isolation and Quantitative PCR
Total RNA was isolated using TRIzol 
reagent (Life Technologies Europe BV) 
and quantity was controlled using a 
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reduction in lipid accumulation in the 
liver, relative expression of several genes 
involved in lipid metabolism was mea-
sured (Figure 3F). Expression of Cd36 
(Cd36 molecule), involved in fatty acid 
uptake and transport, was significantly 
decreased in NE–/–/PR3–/– (p = 0.0073), 
but not in NE–/–/CG–/– mice, when com-
pared with wild-type mice. Fabp1 (fatty 
acid-binding protein 1), a gene involved 
in intracellular fatty acid transport, was 
downregulated in NE–/–/CG–/– mice  
(p = 0.0297), but not in NE–/–/PR3–/– mice. 
In addition, two genes involved in lipo-
genesis (diacylglycerol O-acyltransferase 
1 [Dgat1] and fatty acid synthase [Fas]) 
were significantly downregulated in 
NE–/–/PR3–/– (p < 0.0001 and p = 0.0002, 
respectively), but not in NE–/–/CG–/– 
high-fat diet. Both NE–/–/CG–/– and NE–/–/PR3–/– 
mice had a significantly reduced liver 
weight and reduced lipid droplets in the 
liver when compared with wild-type mice 
(p = 0.0035 and p < 0.0001, respectively). 
In accordance, liver triglyceride levels 
were significantly decreased in both  
NE–/–/CG–/– (p = 0.0001) and NE–/–/PR3–/–  
(p < 0.0001) mice when compared with 
those of wild-type mice (Figures 3D, E). 
Strikingly, and despite similar body-
weight gain upon high–fat-diet feeding, 
NE–/–/PR3–/– mice displayed a signif-
icant reduction in liver weight and lipid 
droplet accumulation in the liver when 
compared with NE–/–/CG–/– mice  
(p < 0.0001).
To identify molecular pathways that 
may be responsible for the observed 
 improved glucose tolerance. Blood glucose 
levels were lower in NE–/–/PR3–/– mice 
after 120 min during the insulin tolerance 
test and after 60 min during the oral glu-
cose tolerance test when compared with 
those of NE–/–/CG–/– mice (p = 0.0034 and 
p = 0.0374,  respectively). However, differ-
ences in AUC values between NE–/–/CG–/– 
and NE–/–/PR3–/– mice were not significant 
for both the insulin tolerance test and the 
oral glucose tolerance test (Figure 3B). 
No differences in plasma insulin levels 
were observed between the three groups 
( Figure 3C).
NAFLD was assessed by quantifying 
lipid droplets in HE-stained liver sec-
tions. Large differences in the quantity  
of lipid droplets in the liver were ob-
served between the three genotypes after 
Figure 2. Relative mRNA expression of proteinase 3, caspase-1, neutrophil elastase and cathepsin G in liver. (A) Relative mRNA expres-
sion of proteinase 3, caspase-1, neutrophil elastase and cathepsin G after 4 wks of diet intervention. (B) Relative mRNA expression of 
proteinase 3, caspase-1, neutrophil elastase and cathepsin G in nonarthritic and arthritic mice. PR3, proteinase 3; NE, neutrophil elas-
tase; CG, cathepsin G; LFD, low-fat diet; HFD, high-fat diet; **significant difference p ≤ 0.01; NS, nonsignificant.
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uptake and lipogenesis are less active 
in livers from NE–/–/PR3–/– mice when 
 compared with NE–/–/CG–/– mice and 
wild-type mice. Altogether, our interim 
conclusion is that these results point 
NE–/–/PR3–/–, but not in NE–/–/CG–/– mice 
compared with wild-type animals 
(p = 0.0065 and p = 0.0037, respectively). 
Overall, gene expression data suggest 
that processes involved in fatty acid 
mice. Also the genes Pparα (peroxisome 
proliferator-activated receptor α) and 
Cpt1a (carnitine palmitoyltransfer-
ase 1A, liver), both involved in fatty 
acid oxidation, were downregulated in 
Figure 3. Improved NAFLD status and metabolic profiles in NE–/–/CG–/– and NE–/–/PR3–/– mice after a high-fat diet. (A) Bodyweight develop-
ment of wild-type (n = 10), NE–/–/CG–/– (n = 15) and NE–/–/PR3–/– (n = 15) mice during diet intervention. (B) Insulin tolerance test and ITT AUC 
values, oral glucose tolerance test and oGTT AUC values of wild-type, NE–/–/CG–/– and NE–/–/PR3–/–. (C) Plasma insulin levels. (D) HE staining 
of liver sections. (E) Percentage of lipid droplets in HE-stained liver sections, liver weights and liver triglycerides levels. (F) Relative mRNA ex-
pression of Cd36, Fabp1, Dgat1, Fas, Ppar α and Cpt1a in liver. HFD, high-fat diet; WT, wild-type; ITT, insulin tolerance test; oGTT, oral glucose 
tolerance test; TG, triglycerides; *significant difference p ≤ 0.05; **significant difference p ≤ 0.01; ***significant difference p ≤ 0.001.
Continued on the next page
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Figure 3. Continued.
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at baseline (p = 0.0021) (Figure 5B) and 
were more insulin resistant, as assessed 
by the insulin tolerance test, when com-
pared with casp-1–/– mice injected with 
vehicle (p = 0.021) (Figure 5C). Plasma 
insulin levels tended to be higher in 
proteinase 3-treated mice but differences 
were not statistically significant (Figure 5D). 
The quantity of lipid droplets in the 
liver, liver weights and liver triglycerides 
were not different between caspase-1–/– 
mice treated with vehicle or proteinase 3 
(Figures 5E, F). In accordance, proteinase 
3 treatment did not affect regulation 
of the hepatic lipid metabolism genes 
Cd36, Fabp1, Dgat1, Fas, Pparα and Cpt1a 
(Supplementary Figure S1). To evaluate 
whether proteinase 3 treatment affects 
the inflammatory status of white adipose 
tissue and liver, macrophage infiltration 
and ex vivo secretion of proinflammatory 
cytokines were determined, but no dif-
ferences between vehicle- and proteinase 
3-treated animals were observed. In 
addition, no differences in expression 
were observed for the inflammatory 
genes IL-1β, Cd68, IL6, Mcp-1 and IL-1Ra 
in either white adipose tissue or liver 
(data not shown). These results indicate 
that the induction of insulin resistance 
by PR3 acts independently of caspase-1. 
Moreover, short-term treatment with 
proteinase 3 enhances basal glucose 
levels and induces insulin resistance 
independent of changes in hepatic 
lipid metabolism or activation of genes 
involved in inflammation. Notably, 
bodyweight was not different between 
proteinase 3- and vehicle-treated ani-
mals, indicating that the observed insulin 
resistance is not caused by differences in 
bodyweight.
Treatment with Human `-1 Antitrypsin 
Decreases Fasting Glucose 
Levels and Reduced Lipid Droplet 
Accumulation in the Liver
We next investigated whether inhi-
bition of neutrophil serine proteases 
would reduce NAFLD and improve in-
sulin resistance in vivo in an established 
 animal model of diet-induced obesity. 
 Wild-type C57BL/6J mice were divided 
significant. No differences in IL-6 levels 
were observed between the two knock-out 
groups (Figure 4D). Also no differences 
in KC (CXCL1) levels were observed 
between the three experimental groups 
(Figure 4E).
To investigate whether the reduction 
in lipid accumulation in livers from 
NE–/–/CG–/– and NE–/–/PR3–/– mice correlated 
with the inflammatory status in the liver, 
we examined the relative expression of 
several inflammatory genes (Figure 4F).  
Interestingly, while mRNA expression 
of IL-1β and Cd68 molecule (Cd68), a 
marker for monocyte and macrophage  
infiltration, were significantly downreg-
ulated in NE–/–/PR3–/– mice when com-
pared with wild-type mice (p = 0.0325 and 
p < 0.0001, respectively), no reduction 
was observed in livers of NE–/–/CG–/– 
mice versus wild-type mice. A similar 
trend was observed for IL6 and mono-
cyte chemotactic protein 1 (Mcp-1). The 
anti-inflammatory gene interleukin-1 
receptor antagonist (IL-1Ra) was down-
regulated in NE–/–/PR3–/– mice when 
compared with wild-type mice  
(p = 0.0085). To conclude this section, 
these results show that NE–/–/CG–/– 
and NE–/–/PR3–/– mice display reduced 
inflammation in adipose tissue as 
compared with wild-type mice. Inter-
estingly, only NE–/–/PR3–/– mice, but not 
NE–/–/CG–/– mice, showed reduced he-
patic inflammation, suggesting that pro-
teinase 3 specifically plays an important 
role in the activation of inflammatory 
pathways in the liver.
Proteinase 3 Induces In Vivo Insulin 
Resistance
To investigate whether the induction 
of insulin resistance and NAFLD by 
proteinase 3 acts through a mechanism 
independently of caspase-1, we treated 
caspase-1–/– mice with proteinase 3 
(0.25 mg/kg in vehicle) or vehicle (PBS) 
during the last 10 d of a 16-wk high-fat 
diet. No differences in bodyweight were 
observed between vehicle- and proteinase 
3-treated animals (Figure 5A). Casp-1–/– 
mice injected with proteinase 3 had  
significantly higher fasting glucose levels 
toward an important role for neutrophil 
serine proteases in the development of 
high–fat–diet-induced obesity, insulin re-
sistance, glucose intolerance and NAFLD. 
Moreover, the absence of proteinase 3 
specifically causes an additional reduc-
tion in lipid accumulation in the liver as 
compared with cathepsin G.
ne–/–/CG–/– and ne–/–/PR3–/– Mice 
Displayed Reduced Inflammation in 
Response to High–Fat-Diet Feeding
Given the role of neutrophil serine pro-
teases in the activation of inflammatory 
processes, we next investigated inflam-
mation in white adipose tissue and liver 
of NE–/–/CG–/–, NE–/–/PR3–/– and wild-type 
mice. Immunohistochemical localization of 
F4/80-positive macrophages in white ad-
ipose tissue of high–fat–diet-fed mice was 
analyzed and showed a strong reduction 
in the number of macrophages in both 
NE–/–/CG–/– (p < 0.0001) and NE–/–/PR3–/– 
mice (p < 0.0001) when compared with 
wild-type mice (Figures 4A, B). No dif-
ferences in the weight of white adipose 
tissue were observed between the groups. 
No significant difference in the number of 
macrophages was observed between the 
two knock-out mice groups. In addition, 
the number of crown-like structures that 
infiltrated the white adipose tissue was 
significantly reduced in both high– 
fat–diet-fed NE–/–/CG–/– (p = 0.0002) and 
NE–/–/PR3–/– mice (p < 0.0001) when com-
pared with wild-type mice (Figure 4C). 
No differences in the number of crown-
like structures were observed between 
NE–/–/CG–/– and NE–/–/PR3–/– mice.
Subsequently, we assessed the  
inflammatory status of white adipose 
tissue ex vivo. After isolation, white ad-
ipose tissue from all three genotypes 
was cultured in medium for 24 h and 
the release of IL-6 and KC (CXCL1) was 
measured. Excretion of IL-6, an interleu-
kin induced by IL-1β, was significantly 
reduced in white adipose tissue explants 
of NE–/–/CG–/– mice (p = 0.069). IL-6 excre-
tion was also reduced in white adipose 
tissue explants of NE–/–/PR3–/– mice when 
compared with those of wild-type mice 
but differences were not statistically 
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Figure 4. NE–/–/CG–/– and NE–/–/PR3–/–mice have reduced inflammation after a high-fat diet. (A) Representative images of immunostain-
ing of the macrophage marker F4/80 in white adipose tissue of wild-type, NE–/–/CG–/–and NE–/–/PR3–/– mice. (B) Average number of mac-
rophages per field. (C) Average number of CLS per field. Secretion of (D) IL-6 and (E) KC by white adipose tissue explants. (F) Relative 
mRNA expression of IL-1b, Cd68, IL-6, Mcp-1 and IL-1Ra in liver. WT, wild-type; HFD, high-fat diet; CLS, crown-like structures; *significant 
difference p ≤ 0.05; **significant difference p ≤ 0.01 ***significant difference p ≤ 0.001; NS, nonsignificant.
P R 3  A N D  N A F L D
2 1 0  |  T o o n e n  e T  A L .  |  M o L  M e D  2 2 : 2 0 2 - 2 1 4 ,  2 0 1 6
(Figure 6B). Despite the decreased fast-
ing glucose levels in the α-1- antitrypsin-
treated group, the insulin tolerance test 
AUC values and insulin levels did not 
differ between the two high-fat diet 
groups ( Supplementary Figures S2A, B). 
NAFLD was assessed by quantifying 
lipid droplets in HE-stained liver 
After treatment, no differences in  
bodyweight were observed between  
vehicle- and α-1-antitrypsin-treated mice  
(Figure 6A). However, fasting glucose 
levels decreased substantially after 
α-1-antitrypsin treatment and were com-
parable with the fasting glucose levels of  
mice receiving the low-fat diet (p = 0.001) 
in  bodyweight-matched treatment 
groups and treated (IP injection every 
other day) either with α-1 antitrypsin 
(Zemaira 2.0 mg/mouse) or vehicle (PBS) 
during the last 10 d of a 16-wk high–
fat–diet- feeding period. As a control, 
low–fat– diet-fed mice were also treated 
with vehicle.
Figure 5. Injected proteinase 3 induces insulin resistance in caspase-1-deficient mice during the last 10 d of a high-fat diet. (A) Body-
weight of caspase-1–/– mice treated with vehicle (n = 10) or proteinase 3 (n = 10) during last 10 d of a high-fat diet. (B) Fasting glucose 
levels at baseline. (C) Glucose levels during insulin tolerance test and ITT AUC values. (D) Plasma insulin levels. (E) HE staining of liver sec-
tions. (F) Percentage of lipid droplets in HE-stained liver sections, liver weights and liver triglycerides. ITT, insulin tolerance test; PR3,  
proteinase 3; TG, triglycerides; *significant difference p ≤ 0.05; **significant difference p ≤ 0.01.
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To identify the underlying path-
ways that may be responsible for the 
 observed reduction in lipid accumula-
tion in the liver after α-1-antitrypsin 
(p = 0.003). Liver weights and triglycer-
ide levels were not different between 
groups after α-1- antitrypsin treatment 
(Figures 6C, D).
sections. Lipid  droplet accumulation 
in the liver was significantly lower in 
mice treated with α-1 antitrypsin when 
compared with mice treated with vehicle 
Figure 6. Treatment with α-1 antitrypsin improves NAFLD status and reduces fasting glucose during the last 10 d of a high-fat diet. 
(A) Bodyweight of mice after a low-fat diet and treated with vehicle and after a high-fat diet treated with either vehicle or α-1 antitryp-
sin. (B) Fasting glucose levels. (C) HE staining of liver sections. (D) Percentage of lipid droplets in HE-stained liver sections, liver weights 
and liver triglycerides. LFD, low-fat diet; HFD, high-fat diet; hAAT, human α-1 antitrypsin; TG, triglycerides; **significant difference p ≤ 0.01; 
***significant difference p ≤ 0.001; NS, nonsignificant.
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in the number of crown-like structures in 
adipose tissue of α-1- antitrypsin-treated 
mice (Figure 7C). Ex vivo culturing of 
white adipose tissue revealed no effect of 
α-1-antitrypsin treatment on the secretion 
of IL-6 and KC ( Figures 7D, E).
Subsequently, we investigated 
whether this reduced inflammatory 
status in the adipose tissue was also 
present in the liver after α-1- antitrypsin 
treatment. The relative expression of 
the genes IL1b, Cd68, IL6, Mcp-1 and 
IL1Ra was evaluated, but no differences 
between vehicle- and α-1- antitrypsin-
treated mice were observed (data not 
shown). In addition, no differences 
in relative expression between the 
Treatment with `-1 Antitrypsin 
Reduces Macrophage Influx into  
the Adipose Tissue
It is a well-known fact that α-1 anti-
trypsin has strong anti-inflammatory 
properties (14). We therefore investigated 
whether α-1 antitrypsin is capable of 
reducing low-grade inflammation as it 
is seen in obesity. The number of F4/80- 
positive macrophages that infiltrated the 
white adipose tissue was substantially 
reduced in high–fat–diet-fed mice treated 
with α-1 antitrypsin when compared with 
high–fat–diet-fed mice treated with vehicle 
(p = 0.0405) ( Figures 7A, B). In line with 
the reduction in macrophage infiltration, 
there was a clear trend toward a reduction 
treatment, the relative expression of 
the genes Cd36, Fabp1 (fatty acid transport 
and uptake), Dgat1, Fas (lipogenesis), 
Pparα and Cpt1a (fatty acid oxidation) 
was evaluated in liver tissue. Although 
these genes were not significantly reg-
ulated after α-1-antitrypsin treatment, 
a trend toward increased expression 
was observed in the α-1-antitrypsin- 
treated group for Dgat1, Fas, Pparα 
and Cpt1a ( Supplementary Figure S3). 
Overall, these results show that inhi-
bition of neutrophil serine proteases 
by α-1 antitrypsin improves fasting 
glucose and reduces lipid droplet ac-
cumulation in the liver of mice fed a 
high-fat diet.
Figure 7. Treatment with human α-1 antitrypsin reduces macrophage infiltration into the adipose tissue during the last 10 d of a high-
fat diet. (A) Representative images of immunostaining of the macrophage marker F4/80 in white adipose tissue of low–fat–diet-fed 
mice treated with vehicle, high–fat–diet-fed mice treated with vehicle and high–fat–diet-fed mice treated with human α-1 antitrypsin. 
(B)  Average number of macrophages per field. (C) Average number of crown-like structures (CLS) per field. Secretion of (D) IL6 and 
(E) KC by white adipose tissue explants. LFD, low-fat diet; HFD, high-fat diet; hAAT, human α-1 antitrypsin; CLS, crown-like structures; 
*P ≤ 0.05; NS, nonsignificant.
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Given the prominent role of IL-1β in  
inflammation-induced T2D and NAFLD  
and the role of neutrophil serine pro-
teases in processing pro-IL-1β into its 
active form, it is a logical next step to 
point out IL-1β as the prime suspect for 
the observed metabolic disturbances. 
However, that is not necessarily the case. 
Besides cytokine processing, neutrophil 
serine proteases are also known to 
regulate other molecular mechanisms in-
volved in inflammation. Neutrophil ser-
ine proteases are able to proteolytically 
modify chemokines such as, for instance, 
CXC-chemokine 8 (CXCL8) (19). They 
also play a role in receptor activation (20) 
and have been shown to cleave cell- 
surface adhesion molecules, thereby 
potentially participating in neutrophil 
migration (21). These examples indicate 
that, in addition to the processing of 
pro-IL-1β, neutrophil serine proteases 
also regulate many other inflammatory 
pathways that might be involved in the 
induction of metabolic complications.
In recent years, it has become evident 
that NAFLD and T2D are complex disor-
ders in which multiple mechanisms are 
involved. In search for new therapeutics, 
the effectiveness of targeting a single 
protein may therefore be limited and a 
more comprehensive approach is needed 
that integrates multiple mechanisms of 
action. In this perspective, α-1 antitryp-
sin is of particular interest as it targets 
multiple inflammatory proteins known 
to be involved in obesity-induced devel-
opment of T2D and NAFLD. Given the 
recent evidence that caspase-1 (5) and 
both neutrophil elastase (8,9) and pro-
teinase 3 (this study) are involved in the 
development of T2D and NAFLD, it is 
very well possible that α-1 antitrypsin ther-
apy would be beneficial for the treat-
ment of these conditions. Mansuy-Aubert  
et al. showed that transgenic mice over-
expressing α-1 antitrypsin are pro-
tected against high–fat–diet-induced 
insulin resistance and NAFLD (9). Our 
results showed that α-1-antitrypsin 
treatment reduced liver lipid content and 
improved fasting glucose. In addition, 
α-1-antitrypsin treatment reduced  
compared with cathepsin G, our results 
point out to a prominent role for pro-
teinase 3 in the development of NAFLD. 
This additional effect of proteinase 3 is 
also seen at the level of transcription. 
Relative expression of genes involved in 
fatty acid uptake and transport (Cd36), 
lipogenesis (Dgat1, Fas) and fatty acid 
oxidation (Pparα, Cpt1a) was downreg-
ulated in livers from NE–/–/PR3–/– mice 
when compared with those of wild-type 
and NE–/–/CG–/– mice. These results sug-
gest that lipid metabolism pathways in 
the liver are, at least partly, regulated by 
proteinase 3. We hypothesized that neu-
trophil serine proteases induce metabolic 
disturbances by altering and/or acti-
vating inflammatory processes. Indeed, 
our results showed that mice deficient 
for NE/CG and NE/PR3 had, in addition 
to the improved metabolic profile, a 
reduced adipose tissue macrophage infil-
tration after high–fat-diet feeding when 
compared with wild-type mice. Also 
here, the results suggest a prominent 
role for proteinase 3 in the liver as the 
relative expression of the inflammatory 
genes IL1b, Cd68 and IL1ra was down-
regulated in livers from NE–/–/PR3–/– mice 
when compared with those of  wild-type 
and NE–/–/CG–/– mice. Also IL6 and Mcp1 
showed a strong tendency toward down-
regulation in livers from NE–/–/PR3–/– 
mice. These results strengthen the hy-
pothesis that neutrophil serine proteases 
induce metabolic dysfunction by the  
activation and/or prolongation of  
inflammatory processes.
The influence of weight differences 
between experimental groups is, as 
a confounding factor, a problem for 
studying metabolic disorders. Although 
bodyweight was different between wild-
type and the two knock-out groups, no 
difference in bodyweight was observed 
between NE–/–/CG–/– and NE–/–/PR3–/– 
mice. Also no differences in bodyweight 
were observed between α-1-antitrypsin- 
and vehicle-treated mice. These results 
indicate that the improved metabolic 
profiles in NE–/–/PR3–/– mice and α-1 
 antitrypsin-treated mice were not caused 
by differences in bodyweight.
groups were observed for the genes 
proteinase 3 (Prtn3), neutrophil elastase 
(Elane) and cathepsin G (Ctsg) (data 
not shown). Overall, these results show 
that treatment with α-1 antitrypsin 
reduces adipose tissue macrophage 
content.
DISCUSSIon
Our results demonstrate that neutrophil 
serine proteases have a prominent role in 
the development of NAFLD and insulin 
resistance. We also show that treatment 
with the neutrophil serine proteases in-
hibitor α-1 antitrypsin strongly reduces 
lipid droplets in the liver, improves fast-
ing glucose levels and decreases adipose 
tissue inflammation in mice with high–
fat–diet-induced NAFLD and insulin 
resistance. Together, these findings pro-
vide evidence that proteinase 3 is a novel 
mechanism involved in the development 
of NAFLD and insulin resistance and that 
inhibition of proteinase 3, combined with 
inhibition of other neutrophil serine pro-
teases, may have therapeutic potential.
Our results, indicating that neutrophil 
serine proteases are involved in the de-
velopment of insulin resistance and 
NAFLD, are supported by others studies 
as well. Recently, it was reported that 
mice deficient for neutrophil elastase 
were resistant to high–fat–diet-induced 
inflammation, insulin resistance (8,9) 
and NAFLD (9). Concerning proteinase 
3, relatively little is known and studies 
investigating the role of endogenous pro-
teinase 3 in models for obesity, insulin 
resistance and NAFLD were lacking. Our 
results provide evidence that, in addi-
tion to neutrophil elastase, endogenous 
proteinase 3 is also important for high–
fat–diet-induced development of obesity, 
insulin resistance and NAFLD. Both 
NE–/–/CG–/– and NE–/–/PR3–/– mice were 
more insulin sensitive when compared 
with wild-type mice. Regarding NAFLD, 
liver lipid content and liver weights were 
reduced in NE–/–/CG–/– mice, and this 
effect was even stronger in NE–/–/PR3–/– 
mice. Given that the absence of protein-
ase 3 specifically causes an additional 
reduction in lipid content in the liver as 
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obesity-induced inflammation. These 
results support our hypothesis that 
α-1-antitrypsin treatment is capable of 
improving metabolic status by reducing 
inflammation.
One limitation of this study is that 
a solo proteinase 3 knock-out mouse 
model is not available. As a result, it is 
difficult to exactly discriminate between 
effects induced by proteinase 3 or  
neutrophil elastase. Another limitation is 
that we were able to test only one dose 
of α-1 antitrypsin. We suggest that in 
future experiments multiple doses of α-1 
antitrypsin need to be tested, thereby 
providing the opportunity to study its 
effects in a dose-response manner.
ConCLUSIon
We identified proteinase 3 as a new fac-
tor involved in NAFLD and insulin resis-
tance. Inhibition of proteinase 3 and other 
neutrophil serine proteases by α-1 anti-
trypsin reduced lipid content in the liver 
and decreased fasting glucose levels and 
therefore may have therapeutic potential.
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